Diagenode

A gene therapy for inherited blindness using dCas9-VPR–mediatedtranscriptional activation


Böhm, Sybille and Splith, Victoria and Riedmayr, Lisa Maria and Rötzer,René Dominik and Gasparoni, Gilles and Nordström, Karl J. V. and Wagner,Johanna Elisabeth and Hinrichsmeyer, Klara Sonnie and Walter, Jörn andWahl-Schott, Christian and Fenske, Stef

Catalytically inactive dCas9 fused to transcriptional activators (dCas9-VPR) enables activation of silent genes. Many disease genes have counterparts, which serve similar functions but are expressed in distinct cell types. One attractive option to compensate for the missing function of a defective gene could be to transcriptionally activate its functionally equivalent counterpart via dCas9-VPR. Key challenges of this approach include the delivery of dCas9-VPR, activation efficiency, long-term expression of the target gene, and adverse effects in vivo. Using dual adeno-associated viral vectors expressing split dCas9-VPR, we show efficient transcriptional activation and long-term expression of cone photoreceptor-specific M-opsin (Opn1mw) in a rhodopsin-deficient mouse model for retinitis pigmentosa. One year after treatment, this approach yields improved retinal function and attenuated retinal degeneration with no apparent adverse effects. Our study demonstrates that dCas9-VPR–mediated transcriptional activation of functionally equivalent genes has great potential for the treatment of genetic disorders.

Tags
Antibody
CRISPR

Share this article

Published
August, 2020

Source

Products used in this publication

  • CRISPR/Cas9 Antibody
    C15310258-100
    CRISPR/Cas9 Antibody

Events

 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics